Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Afatinib

A targeted cancer medicine that blocks receptors of the ErbB family (EGFR, HER2 and HER4), approved in the United States in 2013 for non-small cell lung cancer with EGFR mutations. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.

Did you know?Unlike first-generation inhibitors, which bind reversibly, it forms a covalent bond with a cysteine residue of the receptor and switches it off permanently.

Afatinib DimaleateGo to the active ingredient →
Afatinib-d6Isotopically labelledAfatinib-d6Cat. No. P-A049-003CAS 1313874-96-2
AfatinibActive ingredientAfatinibCat. No. P-A049-018CAS 850140-72-6

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.